Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

Two-year study shows efficacy of immunotherapy drug in 12 mismatch-repair deficient cancers that failed to respond to prior treatment

Following a two-year study, researchers predict that in future it will become standard to test for MMR deficiency in patients with refractory cancer, regardless of tumour type